Radiosynthesis and Preclinical Evaluation of an <sup>18</sup>F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A)

Radiosynthesis and Preclinical Evaluation of an <sup>18</sup>F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A)

The cyclic nucleotide phosphodiesterase 2A is an intracellular enzyme which hydrolyzes the secondary messengers cAMP and cGMP and therefore plays an important role in signaling cascades. A high expression in distinct brain areas as well as in cancer cells makes PDE2A an interesting therapeutic and d...

Full description

Bibliographic Details
Main Authors: Barbara Wenzel, Stefan R. Fritzsche, Magali Toussaint, Detlef Briel, Klaus Kopka, Peter Brust, Matthias Scheunemann, Winnie Deuther-Conrad
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Pharmaceuticals
Subjects:
PDE2A inhibitor
triazolopyridopyrazine
fluorine-18
small animal PET-MR
autoradiography
in vivo metabolism
Online Access:https://www.mdpi.com/1424-8247/15/10/1272

Internet

https://www.mdpi.com/1424-8247/15/10/1272

Similar Items